Angiogenesis during implantation, and placental and early embryonic development

Placenta

Volumn 22, Issue 1, 2001, Pages 1-13

  Sherer, D M ^a   Abulafia, O ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

ANEMIA; ANGIOGENESIS; ARTICLE; CAPILLARY; DECIDUALIZATION; EMBRYO DEVELOPMENT; EMBRYO GROWTH; FIRST TRIMESTER PREGNANCY; GROWTH INHIBITION; HUMAN; HYPOXIA; IMMUNITY; IMPLANTATION; INFLAMMATION; MEDICAL INFORMATION; MEDICAL LITERATURE; NEOPLASM; NONHUMAN; OVULATION; PATHOLOGY; PHYSIOLOGY; PLACENTA DEVELOPMENT; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; REPRODUCTION; TUMOR GROWTH; WOUND HEALING; YOLK SAC;

EID: 0035145583     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1053/plac.2000.0588     Document Type: Article

References (106)

1. Angiogenesis of the endometrium
2. Angiogenesis of the ovary
3. Colocalization of vascular endothelial growth factor and its Flt-1 receptor in human placenta
4. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
5. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1
6. Fetal and placental size and risk of hypertension in adult life
7. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyte implantation
8. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
9. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development
10. Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing
11. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
12. Differential expression of vascular endothelial growth factor and its receptor mRNAs in the mouse uterus around the time of implantation
13. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells
14. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and blastocyte contains mRNA for the receptor at this time
15. Identification and localization of alternatively spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial cell lines
16. Vascular endothelial growth factor: Possible role in fetal development and placental function
17. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy
18. Comparison of expression patterns for placental growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation
19. A vascular endothelial growth factor antgonist is produced by the human placenta and released into the maternal circulation
20. Developmental expression of myeloid leukemia inhibitory factor gene in preimplantation blastocytes and in extraembryonic tissue of mouse embryos
21. VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia
22. Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation
23. Thalidomide is an inhibitor of angiogenesis
24. Expression of vascular endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-implantation rabbit uterus
25. Defective haemopoiesis and vasculogenesis in transforming growth factor β1 knock out mice
26. Vascularization of the mouse embryo: A study of flt-1, tck, tie, and vascular endothelial growth factor expression during development
27. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
28. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
29. Solution structure of the heparin-binding domain of vascular endothelial growth factor
30. Heterogeneous embryonic lethality induced by targeted inactivation of the VEGF gene
31. Tumor angiogenesis
32. How is blood vessel growth regulated in normal and neoplastic tissue?
33. What is the evidence that tumors are angiogenesis dependent?
34. Angiogenic factors
35. Increased hemangioblast commitment, not vascular disorganization, is primary defect in flt-1 knockout mice
36. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
37. Molecular cloning and expression of cDNA encoding a murine myeloid leukemia (LIF)
38. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia
39. Embryonic death of Mek-deficient mice reveals a role for this kinase in angiogenesis in the labryrinthine region of the placenta
40. Angiogenesis in the female reproductive tract
41. Immunochemical location of platelet-derived growth factor in placenta and its possible role in preeclampsia
42. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (Flt-1) pre-mRNA is important for the regulation of VEGF activity
43. Sites of endometrial vascular leakage during implantation in the rabbit
44. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression
45. Vectorial secretion of vascular endothelial growth factor by polarized human endometrial epithelial cells
46. Localization of two angiogenic factors (PDECGF and VEGF) in human placentae throughout gestation
47. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis
48. Increased fetoplacental angiogenesis during first-trimester in anaemic women
49. A requirement for neuropilin-1 in embryonic vessel formation
50. Specificity of vascular endothelial growth factor receptor ligand binding domains
51. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: Molecular evidence for 'placental hyperoxia' in intrauterine growth restriction
52. Localization of placenta growth factor (PIGF) in human term placenta
53. Oxygen and placental villous development: Origins of fetal hypoxia
54. Neuropilin-1-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice
55. Regulation of angiogenesis
56. Vascular endothelial growth factors and its receptors
57. Critical components of the female reproductive pathways are supressed by the angiogenesis inhibitor AGM-1470
58. Angiopoietin-1 induces sprouting angiogenesis in vitro
59. ARNT-deficient mice and placental differentiation
60. Transforming growth factor-beta 1 null mutation in mice causes excessive inflammatory response and early death
61. Defective angiogenesis in mice lacking endoglin
62. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and pre-eclampsia
63. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
64. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14
65. Abnormal angiogenesis and response to glucose and oxygen deprivation in mice lacking the protein ARNT
66. Neuropilin-1 is a placenta growth factor-2 receptor
67. High affinity VEGF binding and developmental expression suggest Flt-1 as a major regulator of vasculogenesis and angiogenesis
68. Vascular endothelial growth factor and its receptors
69. Elevated levels of angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patient
70. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
71. Angiostatin induces and sustains dormancy of human primary tumors in mice
72. Placenta growth factor. Potentiation of vascular endothelial growth factor bioreactivity, in vitro and in vivo and high affinity to flt-1 but not flt-q/KDR
73. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro
74. Immunohistochemical localization of growth factors and intermediate filaments during the establishment of the porcine placenta
75. Vasculogenesis and angiogenesis: Two distinct morphogenetic mechanisms establish embryonic vascular pattern
76. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in embryonic vascular endothelium
77. Developmental expression of PDGF, TGF-α, and TGF-β in preimplantation mouse embryos
78. Placental pathologic features of preterm preeclampsia
79. Characterization of TEK receptor tyrosine kinase and its ligannds, Angiopoietins, in human hematopoitic progenitor cells
80. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
81. Leukemia inhibitory factor produced at the fetomaternal interface stimulates chorionic gonadotropin production: Its possible implication during pregnancy, including implantation period
82. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
83. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
84. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and pregnancies complicated by preeclampsia
85. Localization of leukemia inhibitory factor and its receptor in human placenta throughout pregnancy
86. Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblast
87. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family
88. Immunohisto-chemical distribution of vascular endothelial growth factor in the human placenta associated with hydrops fetalis
89. Targeted disruption of the mouse transforming growth-beta 1 gene results in multifocal inflammatory disease
90. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast
91. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast
92. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonal regulated angiogenesis
93. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
94. Fetal growth in maternal anemia
95. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor
96. Requisite role of angipoietin-1, a ligand for the TIE2 receptor, during angiogenesis
97. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta
98. Placenta growth factor: Potential role in pregnancy
99. Preeclampsia is associated with reduced serum levels of placenta growth factor
100. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans
101. Targeted disruption of the low-affinity leukemia factor-receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death
102. Angiogenesis and the placental environment
103. Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells
104. The role of aryl hydrocarbon nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells
105. Characterization of pure human first-trimester cytotrophoblast cells in long-term culture: Growth pattern, markers, and hormone production
106. Placental growth factor-1 is chemotactic, mitogenic, and angiogenic